HCM
ACAD icon

Harvey Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Harvey Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-219,042
Closed -$4.92M – 78
2018
Q1 		$4.92M Buy
219,042
+200
+0.1% +$5.54K 1.84% 24
2017
Q4 		$6.59M Sell
218,842
-11,858
-5% -$379K 2.39% 17
2017
Q3 		$8.69M Sell
230,700
-1,450
-0.6% -$47.2K 3.51% 8
2017
Q2 		$6.47M Buy
232,150
+1,800
+0.8% +$53.6K 2.78% 13
2017
Q1 		$7.92M Sell
230,350
-21,475
-9% -$758K 3.56% 8
2016
Q4 		$7.26M Sell
251,825
-81,000
-24% -$2.14M 3.38% 8
2016
Q3 		$10.6M Sell
332,825
-19,375
-6% -$657K 3.27% 3
2016
Q2 		$11.4M Sell
352,200
-65,325
-16% -$2.19M 5.73% 2
2016
Q1 		$11.7M Sell
417,525
-15,800
-4% -$345K 5.66% 2
2015
Q4 		$15.4M Sell
433,325
-7,450
-2% -$262K 6.1% 2
2015
Q3 		$14.6M Sell
440,775
-3,650
-0.8% -$152K 5.82% 2
2015
Q2 		$18.5M Sell
444,425
-58,875
-12% -$2.28M 6.27% 2
2015
Q1 		$16.4M Sell
503,300
-74,400
-13% -$2.56M 6.03% 3
2014
Q4 		$18.3M Buy
577,700
+1,500
+0.3% +$42.5K 7.03% 2
2014
Q3 		$14.3M Sell
576,200
-2,000
-0.3% -$46.8K 5.59% 4
2014
Q2 		$13.1M Buy
578,200
+19,950
+4% +$417K 4.67% 6
2014
Q1 		$13.6M Buy
558,250
+18,800
+3% +$476K 5.42% 4
2013
Q4 		$13.5M Buy
539,450
+31,450
+6% +$742K 5.57% 2
2013
Q3 		$14M Buy
508,000
+1,600
+0.3% +$33.4K 7.08% 2
2013
Q2 		$9.19M Buy
+506,400
New +$6.98M 5.7% 2

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Harvey Capital Management's ACAD Position: Q2 2018 in Review

Harvey Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2018, closing a stake of 219,042 shares — an estimated $4.92M sold.

Harvey Capital Management first reported a position in ACAD in Q2 2013 and held it in 20 quarters. The position peaked at $18.5M in Q2 2015. 186 funds tracked by Wall St. Rank hold ACAD as of Q2 2018.

  • Harvey Capital Management reported no remaining Acadia Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Harvey Capital Management sold 219,042 Acadia Pharmaceuticals shares in Q2 2018, an estimated $4.92M.
  • Harvey Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 20 quarters.
  • Harvey Capital Management's Acadia Pharmaceuticals position peaked at $18.5M in Q2 2015.
  • 186 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2018.

Based on Harvey Capital Management's 13F filing for Q2 2018, filed 7 Aug 2018.